Want to see HK:2157 full AI Analyst Report?
Lepu Biopharma Co. Ltd. Class H (2157) AI Stock Analysis
Top Page
Lepu Biopharma Co. Ltd. Class H
(HKEX:2157)
The score is driven primarily by mixed financial performance: a notable profitability and revenue inflection in 2025 is offset by continued negative operating/free cash flow and a meaningful debt load. Technically, the stock remains in a downtrend below key moving averages with weak momentum, while valuation appears mid-range based on the P/E.
Lepu Biopharma Co. Ltd. Class H (2157) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 5.69B
- Dividend Yield
- ―
- Average Volume (3M)
- 10.95M
- Price to Earnings (P/E)
- 19.8
- Beta (1Y)
- 0.65
- Revenue Growth
- 46.90%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 646
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lepu Biopharma Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The c...
How the Company Makes Money
The company makes money primarily through (1) sales of approved pharmaceutical products (where it has obtained marketing authorization and commercializes products in its target markets), and (2) out-licensing and collaboration arrangements related to...
Lepu Biopharma Co. Ltd. Class H Financial Statement Overview
Summary
Income statement shows a strong 2025 turnaround with rapid revenue growth and very high gross margins, but balance-sheet leverage remains meaningful and cash generation is weak. Negative operating and free cash flow in 2025 despite profitability raises sustainability and funding-risk concerns.
Income Statement
64PositiveBalance Sheet
55NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 976.31M | 910.67M | 367.79M | 225.35M | 15.57M | 0 |
| Gross Profit | 772.15M | 732.10M | 292.97M | 197.07M | 13.57M | -114.79M |
| EBITDA | 165.07M | 178.73M | -295.67M | 86.95M | -596.53M | -848.43M |
| Net Income | 242.97M | 254.60M | -411.38M | -22.10M | -689.05M | -1.01B |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.10B | 2.28B | 2.38B | 2.53B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 788.84M | 959.17M | 464.91M | 489.64M | 678.20M | 205.17M |
| Total Debt | 1.18B | 1.06B | 850.16M | 746.82M | 690.30M | 335.26M |
| Total Liabilities | 1.76B | 1.72B | 1.60B | 1.50B | 1.63B | 1.23B |
| Stockholders Equity | 1.41B | 1.39B | 702.83M | 896.90M | 900.76M | 836.71M |
Cash Flow | ||||||
| Free Cash Flow | -258.47M | -82.80M | -258.14M | -292.04M | -591.38M | -835.12M |
| Operating Cash Flow | -187.08M | -38.56M | -196.39M | -250.84M | -480.93M | -621.74M |
| Investing Cash Flow | -281.85M | -149.19M | -61.75M | 18.26M | -74.66M | -3.89M |
| Financing Cash Flow | 674.66M | 620.94M | 232.08M | -11.01M | 1.03B | 380.31M |
Lepu Biopharma Co. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2157, the sentiment is Negative. The current price of 3.15 is below the 20-day moving average (MA) of 3.66, below the 50-day MA of 3.91, and below the 200-day MA of 4.54, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 38.38 is Neutral, neither overbought nor oversold. The STOCH value of 4.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2157.
Lepu Biopharma Co. Ltd. Class H Peers Comparison
Overall Rating
HK:180181Outperform
HK:226981Outperform
HK:154871Outperform
HK:269664.6Neutral- HK:215753Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1801 | 81Outperform | HKD 139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% |
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:1801 | Innovent Biologics | 79.75 | -10.45 | -11.59% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Lepu Biopharma Co. Ltd. Class H Corporate Events
Lepu Biopharma Chair Lifts Stake, Signals Confidence in Growth Outlook
Lepu Biopharma Co., Ltd. announced that its chairman, executive director and controlling shareholder, Dr. Pu Zhongjie, has increased his stake in the company by purchasing 1,050,000 H shares on October 27, 2026 via Shanghai-Hong Kong Stock Connect. T...
Lepu Biopharma Posts Strong Clinical Data Across Key Oncology ADC Programs
Lepu Biopharma reported positive Phase III results for its CLDN18.2-targeting antibody-drug conjugate CMG901 (sonesitatug vedotin), showing a significant overall survival benefit over investigator’s choice therapy in second-line and later advan...
Lepu Biopharma’s ADC and IO Pipeline Earns Prime Spots at 2026 ESMO Congress
Lepu Biopharma announced that four of its oncology clinical studies have been selected for presentation at the 2026 European Society for Medical Oncology Congress in Madrid, underscoring growing international recognition of its R&D pipeline. The...
Lepu Biopharma Delivers Revenue Growth as ADC Pipeline Advances
Lepu Biopharma reported interim revenue of about RMB522.4 million for the first half of 2026, up 12.1% year-on-year, driven by domestic sales of its cancer drugs MEIYOUHENG and PUYOUHENG and licensing milestone income from CMG901 and MRG007. The comp...
Lepu Biopharma Schedules Board Meeting to Review 2026 Interim Results and Potential Dividend
Lepu Biopharma Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, has a board that includes executive, non-executive and independent non-executive directors led by Chairman and Executive Director Dr. Pu Zhongjie and CEO and Executive Di...
Lepu Biopharma’s Claudin 18.2 ADC CMG901 Delivers Positive Global Phase III Gastric Cancer Data
Lepu Biopharma reported that its Claudin 18.2-targeting antibody-drug conjugate CMG901, licensed globally to AstraZeneca, achieved positive top-line results in the CLARITY-Gastric01 global Phase III trial for second- and later-line treatment of advan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026